News Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN to Present at The UBS Specialty Pharmaceuticals Conference

CHAPEL HILL, N.C., Jun 15, 2011 (BUSINESS WIRE) -- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Elizabeth Cermak, the Company's Executive Vice President and Chief Commercial Officer, will participate in the UBS Specialty Pharmaceuticals Mini 1x1 Conference on Monday, June 27, 2011 in Boston.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI toxicity. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: www.pozen.com.

SOURCE: POZEN Inc.

POZEN Inc.
Bill Hodges
Chief Financial Officer
919-913-1030
or
Stephanie Bonestell
Manager, Investor Relations & Public Relations
919-913-1030


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.